相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
Radu Pirlog et al.
CANCERS (2022)
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases
Richard S. P. Huang et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
KRAS(G12C)/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (>= 50%) lung adenocarcinoma
Nikolaj Frost et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
PD-L1 testing in urothelial bladder cancer: essentials of clinical practice
Mathieu Rouanne et al.
WORLD JOURNAL OF UROLOGY (2021)
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Meichen Gu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay
Matthew Evans et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
Birgit Guldhammer Skov et al.
MODERN PATHOLOGY (2020)
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2020)
Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor
Sousuke Kubo et al.
ANTICANCER RESEARCH (2020)
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Hao Sun et al.
EBIOMEDICINE (2020)
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Giandomenico Roviello et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer
Zheng Liu et al.
ONCOIMMUNOLOGY (2020)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience
Javier Torralvo et al.
CANCER GENOMICS & PROTEOMICS (2019)
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
Feifei Teng et al.
CANCER LETTERS (2018)
Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis
Fausto Petrelli et al.
CLINICAL LUNG CANCER (2018)
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice
Passiglia Francesco et al.
FUTURE ONCOLOGY (2018)
Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients
Alexander T. Falk et al.
LUNG CANCER (2018)
PD-L1 expression according to the EGFR status in primary lung adenocarcinoma
Kazuki Takada et al.
LUNG CANCER (2018)
Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma
Pierre Serra et al.
LUNG CANCER (2018)
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Irene Ferrer et al.
LUNG CANCER (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
Hyojin Kim et al.
PLOS ONE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
Bo Lan et al.
Oncotarget (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas
Sehui Kim et al.
EUROPEAN JOURNAL OF CANCER (2017)
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
Pedro N. Aguiar et al.
IMMUNOTHERAPY (2017)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti et al.
LUNG CANCER (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
Haitao Yang et al.
ONCOTARGET (2017)
The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
Shafei Wu et al.
ONCOTARGET (2017)
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
Jung Han Kim et al.
ONCOTARGET (2017)
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
Birgit G. Skov et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes
Jin Li et al.
JOURNAL OF THORACIC DISEASE (2017)
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy
Steffen Filskov Sorensen et al.
TRANSLATIONAL ONCOLOGY (2016)
KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
Wei Pan et al.
ONCOTARGET (2016)
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Francesco Passiglia et al.
ONCOTARGET (2016)
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
Andreas H. Scheel et al.
ONCOIMMUNOLOGY (2016)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Antonio Calles et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population
Birgit G. Skov et al.
APMIS (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Luisa Carbognin et al.
PLOS ONE (2015)
EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice
S. Gahr et al.
BRITISH JOURNAL OF CANCER (2013)
The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
Christian Boch et al.
BMJ OPEN (2013)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
分享论文
